# PeptideScanner evidence objects: Ganirelix

Every published version of the records placed with Ganirelix, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/ganirelix.json. Selected public evidence only; not medical advice.

- Objects: 42
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00225433-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT00225433

> PeptideScanner retained ClinicalTrials.gov record NCT00225433 at 2026-11-15T22:03:26.540Z. Its registry update date was 2015-12-03, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct00225433-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-12-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00225433-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00225433-ganirelix-v1
- Content SHA-256: `11118befe1a235dd0561287eee32b30a180e299b6a5117af54e9624b686bc9b0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00225433 ([`ctg-observation-nct00225433-2015-12-03-9c7365d5157f`](#source-ctg-observation-nct00225433-2015-12-03-9c7365d5157f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00225433 at 2026-11-15T22:03:26.540Z. Its registry update date was 2015-12-03, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00225433-2015-12-03-9c7365d5157f`](#source-ctg-observation-nct00225433-2015-12-03-9c7365d5157f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00225433 at 2026-11-15T22:03:26.540Z. Its registry update date was 2015-12-03, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00225433-2015-12-03-9c7365d5157f`](#source-ctg-observation-nct00225433-2015-12-03-9c7365d5157f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00225433-2015-12-03-9c7365d5157f`](#source-ctg-observation-nct00225433-2015-12-03-9c7365d5157f))

### Sources

<a id="source-ctg-observation-nct00225433-2015-12-03-9c7365d5157f"></a>
- **ClinicalTrials.gov record NCT00225433 · retained source version 2015-12-03:9c7365d5157f5a46a8de7c96f3aac5d10b9421a0fe8c288a773c7911fa797ab7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00225433) (`ctg-observation-nct00225433-2015-12-03-9c7365d5157f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00225433." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00225433-ganirelix-v1 SHA-256: 11118befe1a235dd0561287eee32b30a180e299b6a5117af54e9624b686bc9b0.

---

<a id="clinicaltrials-gov-nct00461422-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT00461422

> PeptideScanner retained ClinicalTrials.gov record NCT00461422 at 2026-11-15T22:03:26.540Z. Its registry update date was 2008-06-27, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct00461422-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2008-06-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00461422-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00461422-ganirelix-v1
- Content SHA-256: `dfea27485a4a830c390c9d53e2d1d5d9f28470071216d75528e58458936b314d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00461422 ([`ctg-observation-nct00461422-2008-06-27-9a9756e8506c`](#source-ctg-observation-nct00461422-2008-06-27-9a9756e8506c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00461422 at 2026-11-15T22:03:26.540Z. Its registry update date was 2008-06-27, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00461422-2008-06-27-9a9756e8506c`](#source-ctg-observation-nct00461422-2008-06-27-9a9756e8506c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00461422 at 2026-11-15T22:03:26.540Z. Its registry update date was 2008-06-27, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00461422-2008-06-27-9a9756e8506c`](#source-ctg-observation-nct00461422-2008-06-27-9a9756e8506c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00461422-2008-06-27-9a9756e8506c`](#source-ctg-observation-nct00461422-2008-06-27-9a9756e8506c))

### Sources

<a id="source-ctg-observation-nct00461422-2008-06-27-9a9756e8506c"></a>
- **ClinicalTrials.gov record NCT00461422 · retained source version 2008-06-27:9a9756e8506c8e0a4d606a1dcc934a68d7f7134301ca13cfd29e0cd99251f200** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00461422) (`ctg-observation-nct00461422-2008-06-27-9a9756e8506c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00461422." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00461422-ganirelix-v1 SHA-256: dfea27485a4a830c390c9d53e2d1d5d9f28470071216d75528e58458936b314d.

---

<a id="clinicaltrials-gov-nct00589134-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT00589134

> PeptideScanner retained ClinicalTrials.gov record NCT00589134 at 2026-11-15T22:03:26.540Z. Its registry update date was 2020-03-30, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct00589134-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-03-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00589134-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00589134-ganirelix-v1
- Content SHA-256: `bd2fb7f1ae270ec41071412393188a6250db2874bdde2b6bf3ea58663a83bfe7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00589134 ([`ctg-observation-nct00589134-2020-03-30-493f4a637a66`](#source-ctg-observation-nct00589134-2020-03-30-493f4a637a66))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00589134 at 2026-11-15T22:03:26.540Z. Its registry update date was 2020-03-30, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00589134-2020-03-30-493f4a637a66`](#source-ctg-observation-nct00589134-2020-03-30-493f4a637a66))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00589134 at 2026-11-15T22:03:26.540Z. Its registry update date was 2020-03-30, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00589134-2020-03-30-493f4a637a66`](#source-ctg-observation-nct00589134-2020-03-30-493f4a637a66))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00589134-2020-03-30-493f4a637a66`](#source-ctg-observation-nct00589134-2020-03-30-493f4a637a66))

### Sources

<a id="source-ctg-observation-nct00589134-2020-03-30-493f4a637a66"></a>
- **ClinicalTrials.gov record NCT00589134 · retained source version 2020-03-30:493f4a637a667a43656bb9c66a0db53f93dc67ba9e1204b4df24ab63590a1a9a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00589134) (`ctg-observation-nct00589134-2020-03-30-493f4a637a66`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00589134." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00589134-ganirelix-v1 SHA-256: bd2fb7f1ae270ec41071412393188a6250db2874bdde2b6bf3ea58663a83bfe7.

---

<a id="clinicaltrials-gov-nct00608062-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT00608062

> PeptideScanner retained ClinicalTrials.gov record NCT00608062 at 2026-11-15T22:03:26.540Z. Its registry update date was 2020-12-24, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct00608062-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-12-24
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00608062-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00608062-ganirelix-v1
- Content SHA-256: `2e365a03439b6dc74c900ad8116e37a5203ef6283781aa8bb2e881441f1ad23b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00608062 ([`ctg-observation-nct00608062-2020-12-24-150aa8d1e333`](#source-ctg-observation-nct00608062-2020-12-24-150aa8d1e333))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00608062 at 2026-11-15T22:03:26.540Z. Its registry update date was 2020-12-24, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00608062-2020-12-24-150aa8d1e333`](#source-ctg-observation-nct00608062-2020-12-24-150aa8d1e333))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00608062 at 2026-11-15T22:03:26.540Z. Its registry update date was 2020-12-24, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00608062-2020-12-24-150aa8d1e333`](#source-ctg-observation-nct00608062-2020-12-24-150aa8d1e333))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00608062-2020-12-24-150aa8d1e333`](#source-ctg-observation-nct00608062-2020-12-24-150aa8d1e333))

### Sources

<a id="source-ctg-observation-nct00608062-2020-12-24-150aa8d1e333"></a>
- **ClinicalTrials.gov record NCT00608062 · retained source version 2020-12-24:150aa8d1e33355aa8ef7697e30846435ddcba225a920ee6fe710ccfd7aa53ce4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00608062) (`ctg-observation-nct00608062-2020-12-24-150aa8d1e333`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00608062." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00608062-ganirelix-v1 SHA-256: 2e365a03439b6dc74c900ad8116e37a5203ef6283781aa8bb2e881441f1ad23b.

---

<a id="clinicaltrials-gov-nct00696800-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT00696800

> PeptideScanner retained ClinicalTrials.gov record NCT00696800 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-06-20, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct00696800-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-06-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00696800-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00696800-ganirelix-v1
- Content SHA-256: `966076030a1bb409412be4a4c39dd1f4482873c1ee1b4ef00f52355ee65c04cf`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00696800 ([`ctg-observation-nct00696800-2024-06-20-2e3fded0e23c`](#source-ctg-observation-nct00696800-2024-06-20-2e3fded0e23c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00696800 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-06-20, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00696800-2024-06-20-2e3fded0e23c`](#source-ctg-observation-nct00696800-2024-06-20-2e3fded0e23c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00696800 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-06-20, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00696800-2024-06-20-2e3fded0e23c`](#source-ctg-observation-nct00696800-2024-06-20-2e3fded0e23c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00696800-2024-06-20-2e3fded0e23c`](#source-ctg-observation-nct00696800-2024-06-20-2e3fded0e23c))

### Sources

<a id="source-ctg-observation-nct00696800-2024-06-20-2e3fded0e23c"></a>
- **ClinicalTrials.gov record NCT00696800 · retained source version 2024-06-20:2e3fded0e23cfa30d945c55c274dccccce6ff3a1b343259e522a8198b5161208** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00696800) (`ctg-observation-nct00696800-2024-06-20-2e3fded0e23c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00696800." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00696800-ganirelix-v1 SHA-256: 966076030a1bb409412be4a4c39dd1f4482873c1ee1b4ef00f52355ee65c04cf.

---

<a id="clinicaltrials-gov-nct00702273-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT00702273

> PeptideScanner retained ClinicalTrials.gov record NCT00702273 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-09-05, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct00702273-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-09-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00702273-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00702273-ganirelix-v1
- Content SHA-256: `bc771d317a64b00514b0bad281b202067c1bdb3a756c16923fc33b9eceebc23e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00702273 ([`ctg-observation-nct00702273-2024-09-05-b474d8cea75d`](#source-ctg-observation-nct00702273-2024-09-05-b474d8cea75d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00702273 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-09-05, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00702273-2024-09-05-b474d8cea75d`](#source-ctg-observation-nct00702273-2024-09-05-b474d8cea75d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00702273 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-09-05, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00702273-2024-09-05-b474d8cea75d`](#source-ctg-observation-nct00702273-2024-09-05-b474d8cea75d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00702273-2024-09-05-b474d8cea75d`](#source-ctg-observation-nct00702273-2024-09-05-b474d8cea75d))

### Sources

<a id="source-ctg-observation-nct00702273-2024-09-05-b474d8cea75d"></a>
- **ClinicalTrials.gov record NCT00702273 · retained source version 2024-09-05:b474d8cea75de5e035d95e5013194a0f3e33653f5fce1c9e8603099add677405** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00702273) (`ctg-observation-nct00702273-2024-09-05-b474d8cea75d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00702273." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00702273-ganirelix-v1 SHA-256: bc771d317a64b00514b0bad281b202067c1bdb3a756c16923fc33b9eceebc23e.

---

<a id="clinicaltrials-gov-nct00703014-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT00703014

> PeptideScanner retained ClinicalTrials.gov record NCT00703014 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-09-19, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct00703014-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-09-19
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00703014-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00703014-ganirelix-v1
- Content SHA-256: `94b7cf7b729bb2be3c14d2fecf80e3a212ee7a4e9d324105c86fbea557093a11`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00703014 ([`ctg-observation-nct00703014-2024-09-19-f15b29c8c0be`](#source-ctg-observation-nct00703014-2024-09-19-f15b29c8c0be))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00703014 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-09-19, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00703014-2024-09-19-f15b29c8c0be`](#source-ctg-observation-nct00703014-2024-09-19-f15b29c8c0be))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00703014 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-09-19, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00703014-2024-09-19-f15b29c8c0be`](#source-ctg-observation-nct00703014-2024-09-19-f15b29c8c0be))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00703014-2024-09-19-f15b29c8c0be`](#source-ctg-observation-nct00703014-2024-09-19-f15b29c8c0be))

### Sources

<a id="source-ctg-observation-nct00703014-2024-09-19-f15b29c8c0be"></a>
- **ClinicalTrials.gov record NCT00703014 · retained source version 2024-09-19:f15b29c8c0be67b31a8d68eec7b6cde4735f3dd3a6f51d2da86589472df431ea** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00703014) (`ctg-observation-nct00703014-2024-09-19-f15b29c8c0be`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00703014." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00703014-ganirelix-v1 SHA-256: 94b7cf7b729bb2be3c14d2fecf80e3a212ee7a4e9d324105c86fbea557093a11.

---

<a id="clinicaltrials-gov-nct00724789-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT00724789

> PeptideScanner retained ClinicalTrials.gov record NCT00724789 at 2026-11-15T22:03:26.540Z. Its registry update date was 2022-02-03, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct00724789-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-02-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00724789-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00724789-ganirelix-v1
- Content SHA-256: `1bd9b2f78d7db39f410b2055545d768e68f1b5727b64106341d6786a9ff00ea9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00724789 ([`ctg-observation-nct00724789-2022-02-03-b43129e28788`](#source-ctg-observation-nct00724789-2022-02-03-b43129e28788))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00724789 at 2026-11-15T22:03:26.540Z. Its registry update date was 2022-02-03, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00724789-2022-02-03-b43129e28788`](#source-ctg-observation-nct00724789-2022-02-03-b43129e28788))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00724789 at 2026-11-15T22:03:26.540Z. Its registry update date was 2022-02-03, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00724789-2022-02-03-b43129e28788`](#source-ctg-observation-nct00724789-2022-02-03-b43129e28788))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00724789-2022-02-03-b43129e28788`](#source-ctg-observation-nct00724789-2022-02-03-b43129e28788))

### Sources

<a id="source-ctg-observation-nct00724789-2022-02-03-b43129e28788"></a>
- **ClinicalTrials.gov record NCT00724789 · retained source version 2022-02-03:b43129e287886ec793e94d54c104e6b4e087848ca2d74618ec61e70c174a613f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00724789) (`ctg-observation-nct00724789-2022-02-03-b43129e28788`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00724789." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00724789-ganirelix-v1 SHA-256: 1bd9b2f78d7db39f410b2055545d768e68f1b5727b64106341d6786a9ff00ea9.

---

<a id="clinicaltrials-gov-nct00734279-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT00734279

> PeptideScanner retained ClinicalTrials.gov record NCT00734279 at 2026-11-15T22:03:26.540Z. Its registry update date was 2017-12-26, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct00734279-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-12-26
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00734279-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00734279-ganirelix-v1
- Content SHA-256: `588a0acb0a003557e7ca5f47b4e1769eba000451c1ad3095b23c3939381c1e43`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00734279 ([`ctg-observation-nct00734279-2017-12-26-afcb7ab0348b`](#source-ctg-observation-nct00734279-2017-12-26-afcb7ab0348b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00734279 at 2026-11-15T22:03:26.540Z. Its registry update date was 2017-12-26, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00734279-2017-12-26-afcb7ab0348b`](#source-ctg-observation-nct00734279-2017-12-26-afcb7ab0348b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00734279 at 2026-11-15T22:03:26.540Z. Its registry update date was 2017-12-26, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00734279-2017-12-26-afcb7ab0348b`](#source-ctg-observation-nct00734279-2017-12-26-afcb7ab0348b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00734279-2017-12-26-afcb7ab0348b`](#source-ctg-observation-nct00734279-2017-12-26-afcb7ab0348b))

### Sources

<a id="source-ctg-observation-nct00734279-2017-12-26-afcb7ab0348b"></a>
- **ClinicalTrials.gov record NCT00734279 · retained source version 2017-12-26:afcb7ab0348bb1eddcef72a09ca2df951a1c20bb3e673c404b93136a841a7205** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00734279) (`ctg-observation-nct00734279-2017-12-26-afcb7ab0348b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00734279." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00734279-ganirelix-v1 SHA-256: 588a0acb0a003557e7ca5f47b4e1769eba000451c1ad3095b23c3939381c1e43.

---

<a id="clinicaltrials-gov-nct00757185-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT00757185

> PeptideScanner retained ClinicalTrials.gov record NCT00757185 at 2026-11-15T22:03:26.540Z. Its registry update date was 2016-07-04, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct00757185-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-07-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00757185-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00757185-ganirelix-v1
- Content SHA-256: `a1f43e05d820cfa21d46350dab2b9f8568ee39db338d76a0631d140afb50f657`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00757185 ([`ctg-observation-nct00757185-2016-07-04-0448a7534a08`](#source-ctg-observation-nct00757185-2016-07-04-0448a7534a08))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00757185 at 2026-11-15T22:03:26.540Z. Its registry update date was 2016-07-04, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00757185-2016-07-04-0448a7534a08`](#source-ctg-observation-nct00757185-2016-07-04-0448a7534a08))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00757185 at 2026-11-15T22:03:26.540Z. Its registry update date was 2016-07-04, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00757185-2016-07-04-0448a7534a08`](#source-ctg-observation-nct00757185-2016-07-04-0448a7534a08))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00757185-2016-07-04-0448a7534a08`](#source-ctg-observation-nct00757185-2016-07-04-0448a7534a08))

### Sources

<a id="source-ctg-observation-nct00757185-2016-07-04-0448a7534a08"></a>
- **ClinicalTrials.gov record NCT00757185 · retained source version 2016-07-04:0448a7534a08db5382ea52bb903e2ada7a4ab2a62635d444c2b95efe3ce69070** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00757185) (`ctg-observation-nct00757185-2016-07-04-0448a7534a08`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00757185." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00757185-ganirelix-v1 SHA-256: a1f43e05d820cfa21d46350dab2b9f8568ee39db338d76a0631d140afb50f657.

---

<a id="clinicaltrials-gov-nct00780858-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT00780858

> PeptideScanner retained ClinicalTrials.gov record NCT00780858 at 2026-11-15T22:03:26.540Z. Its registry update date was 2015-05-06, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct00780858-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-05-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00780858-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00780858-ganirelix-v1
- Content SHA-256: `2bacca2c290762641c959d18dd2b1cd67a4f2f051bf43d4d746c78af114c5d24`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00780858 ([`ctg-observation-nct00780858-2015-05-06-1dc49790c6ff`](#source-ctg-observation-nct00780858-2015-05-06-1dc49790c6ff))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00780858 at 2026-11-15T22:03:26.540Z. Its registry update date was 2015-05-06, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00780858-2015-05-06-1dc49790c6ff`](#source-ctg-observation-nct00780858-2015-05-06-1dc49790c6ff))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00780858 at 2026-11-15T22:03:26.540Z. Its registry update date was 2015-05-06, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00780858-2015-05-06-1dc49790c6ff`](#source-ctg-observation-nct00780858-2015-05-06-1dc49790c6ff))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00780858-2015-05-06-1dc49790c6ff`](#source-ctg-observation-nct00780858-2015-05-06-1dc49790c6ff))

### Sources

<a id="source-ctg-observation-nct00780858-2015-05-06-1dc49790c6ff"></a>
- **ClinicalTrials.gov record NCT00780858 · retained source version 2015-05-06:1dc49790c6ff2d5eccd9c5bb6fdcad05498930314f5108ab220a8ffcdad2f78b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00780858) (`ctg-observation-nct00780858-2015-05-06-1dc49790c6ff`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00780858." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00780858-ganirelix-v1 SHA-256: 2bacca2c290762641c959d18dd2b1cd67a4f2f051bf43d4d746c78af114c5d24.

---

<a id="clinicaltrials-gov-nct00802360-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT00802360

> PeptideScanner retained ClinicalTrials.gov record NCT00802360 at 2026-11-15T22:03:26.540Z. Its registry update date was 2011-11-02, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct00802360-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-11-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00802360-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00802360-ganirelix-v1
- Content SHA-256: `1efe0918ae86fec025969da6d4f5da0784837096f3c49906011b567eb2a80d64`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00802360 ([`ctg-observation-nct00802360-2011-11-02-73e5784f910a`](#source-ctg-observation-nct00802360-2011-11-02-73e5784f910a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00802360 at 2026-11-15T22:03:26.540Z. Its registry update date was 2011-11-02, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00802360-2011-11-02-73e5784f910a`](#source-ctg-observation-nct00802360-2011-11-02-73e5784f910a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00802360 at 2026-11-15T22:03:26.540Z. Its registry update date was 2011-11-02, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00802360-2011-11-02-73e5784f910a`](#source-ctg-observation-nct00802360-2011-11-02-73e5784f910a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00802360-2011-11-02-73e5784f910a`](#source-ctg-observation-nct00802360-2011-11-02-73e5784f910a))

### Sources

<a id="source-ctg-observation-nct00802360-2011-11-02-73e5784f910a"></a>
- **ClinicalTrials.gov record NCT00802360 · retained source version 2011-11-02:73e5784f910a33a8d300dfcaaa2471e4a6ea772e9263a6e2bf69403e350aa76a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00802360) (`ctg-observation-nct00802360-2011-11-02-73e5784f910a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00802360." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00802360-ganirelix-v1 SHA-256: 1efe0918ae86fec025969da6d4f5da0784837096f3c49906011b567eb2a80d64.

---

<a id="clinicaltrials-gov-nct00823004-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT00823004

> PeptideScanner retained ClinicalTrials.gov record NCT00823004 at 2026-11-15T22:03:26.540Z. Its registry update date was 2013-12-23, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct00823004-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-12-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00823004-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00823004-ganirelix-v1
- Content SHA-256: `dd7e02d8dd2525f5f9b08974db7dc20650d9278924239c021dfd78b713b7f25e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00823004 ([`ctg-observation-nct00823004-2013-12-23-f3462ab2d12d`](#source-ctg-observation-nct00823004-2013-12-23-f3462ab2d12d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00823004 at 2026-11-15T22:03:26.540Z. Its registry update date was 2013-12-23, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00823004-2013-12-23-f3462ab2d12d`](#source-ctg-observation-nct00823004-2013-12-23-f3462ab2d12d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00823004 at 2026-11-15T22:03:26.540Z. Its registry update date was 2013-12-23, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00823004-2013-12-23-f3462ab2d12d`](#source-ctg-observation-nct00823004-2013-12-23-f3462ab2d12d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00823004-2013-12-23-f3462ab2d12d`](#source-ctg-observation-nct00823004-2013-12-23-f3462ab2d12d))

### Sources

<a id="source-ctg-observation-nct00823004-2013-12-23-f3462ab2d12d"></a>
- **ClinicalTrials.gov record NCT00823004 · retained source version 2013-12-23:f3462ab2d12df62d125cefb79d7926ad487a99222e9d2e51286b7431c1509733** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00823004) (`ctg-observation-nct00823004-2013-12-23-f3462ab2d12d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00823004." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00823004-ganirelix-v1 SHA-256: dd7e02d8dd2525f5f9b08974db7dc20650d9278924239c021dfd78b713b7f25e.

---

<a id="clinicaltrials-gov-nct00988260-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT00988260

> PeptideScanner retained ClinicalTrials.gov record NCT00988260 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-08-15, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct00988260-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-08-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00988260-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00988260-ganirelix-v1
- Content SHA-256: `1991d117175b20360d046f39a294ac4a763884aea083c75f1836393c4aa81de4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00988260 ([`ctg-observation-nct00988260-2024-08-15-1328a96bef2b`](#source-ctg-observation-nct00988260-2024-08-15-1328a96bef2b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00988260 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-08-15, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00988260-2024-08-15-1328a96bef2b`](#source-ctg-observation-nct00988260-2024-08-15-1328a96bef2b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00988260 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-08-15, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct00988260-2024-08-15-1328a96bef2b`](#source-ctg-observation-nct00988260-2024-08-15-1328a96bef2b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00988260-2024-08-15-1328a96bef2b`](#source-ctg-observation-nct00988260-2024-08-15-1328a96bef2b))

### Sources

<a id="source-ctg-observation-nct00988260-2024-08-15-1328a96bef2b"></a>
- **ClinicalTrials.gov record NCT00988260 · retained source version 2024-08-15:1328a96bef2b66751679a9cd7ea193a496447926bc4bd83dd3e34a26a41c768f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00988260) (`ctg-observation-nct00988260-2024-08-15-1328a96bef2b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00988260." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct00988260-ganirelix-v1 SHA-256: 1991d117175b20360d046f39a294ac4a763884aea083c75f1836393c4aa81de4.

---

<a id="clinicaltrials-gov-nct01153581-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT01153581

> PeptideScanner retained ClinicalTrials.gov record NCT01153581 at 2026-11-15T22:03:26.540Z. Its registry update date was 2018-12-13, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct01153581-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-12-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01153581-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct01153581-ganirelix-v1
- Content SHA-256: `b5c3daa7a5870000d228b453b18509e9e40752feaa662a302359d5395d99716e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01153581 ([`ctg-observation-nct01153581-2018-12-13-fccff2a54579`](#source-ctg-observation-nct01153581-2018-12-13-fccff2a54579))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01153581 at 2026-11-15T22:03:26.540Z. Its registry update date was 2018-12-13, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct01153581-2018-12-13-fccff2a54579`](#source-ctg-observation-nct01153581-2018-12-13-fccff2a54579))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01153581 at 2026-11-15T22:03:26.540Z. Its registry update date was 2018-12-13, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct01153581-2018-12-13-fccff2a54579`](#source-ctg-observation-nct01153581-2018-12-13-fccff2a54579))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01153581-2018-12-13-fccff2a54579`](#source-ctg-observation-nct01153581-2018-12-13-fccff2a54579))

### Sources

<a id="source-ctg-observation-nct01153581-2018-12-13-fccff2a54579"></a>
- **ClinicalTrials.gov record NCT01153581 · retained source version 2018-12-13:fccff2a54579aa8d7a3a6601dbcde66f3638794f0033dffe79a9b45270dfe46f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01153581) (`ctg-observation-nct01153581-2018-12-13-fccff2a54579`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01153581." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct01153581-ganirelix-v1 SHA-256: b5c3daa7a5870000d228b453b18509e9e40752feaa662a302359d5395d99716e.

---

<a id="clinicaltrials-gov-nct01286051-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT01286051

> PeptideScanner retained ClinicalTrials.gov record NCT01286051 at 2026-11-15T22:03:26.540Z. Its registry update date was 2013-03-20, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct01286051-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-03-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01286051-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct01286051-ganirelix-v1
- Content SHA-256: `2efa8991102704b4e352b08fb94cf161da7609bbb0a1266bbde6922e4026efe9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01286051 ([`ctg-observation-nct01286051-2013-03-20-94572deb0748`](#source-ctg-observation-nct01286051-2013-03-20-94572deb0748))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01286051 at 2026-11-15T22:03:26.540Z. Its registry update date was 2013-03-20, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct01286051-2013-03-20-94572deb0748`](#source-ctg-observation-nct01286051-2013-03-20-94572deb0748))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01286051 at 2026-11-15T22:03:26.540Z. Its registry update date was 2013-03-20, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct01286051-2013-03-20-94572deb0748`](#source-ctg-observation-nct01286051-2013-03-20-94572deb0748))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01286051-2013-03-20-94572deb0748`](#source-ctg-observation-nct01286051-2013-03-20-94572deb0748))

### Sources

<a id="source-ctg-observation-nct01286051-2013-03-20-94572deb0748"></a>
- **ClinicalTrials.gov record NCT01286051 · retained source version 2013-03-20:94572deb0748d2d4661bc9ae53279d4a42f0c749cd5b1c3f45b55c8d4f03a030** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01286051) (`ctg-observation-nct01286051-2013-03-20-94572deb0748`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01286051." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct01286051-ganirelix-v1 SHA-256: 2efa8991102704b4e352b08fb94cf161da7609bbb0a1266bbde6922e4026efe9.

---

<a id="clinicaltrials-gov-nct01304511-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT01304511

> PeptideScanner retained ClinicalTrials.gov record NCT01304511 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-04-03, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct01304511-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-04-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01304511-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct01304511-ganirelix-v1
- Content SHA-256: `6f93da6eb617d477353c7abd16ca49048010fdabc40667978deb078c336b82dc`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01304511 ([`ctg-observation-nct01304511-2024-04-03-78215f11e840`](#source-ctg-observation-nct01304511-2024-04-03-78215f11e840))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01304511 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-04-03, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct01304511-2024-04-03-78215f11e840`](#source-ctg-observation-nct01304511-2024-04-03-78215f11e840))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01304511 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-04-03, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct01304511-2024-04-03-78215f11e840`](#source-ctg-observation-nct01304511-2024-04-03-78215f11e840))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01304511-2024-04-03-78215f11e840`](#source-ctg-observation-nct01304511-2024-04-03-78215f11e840))

### Sources

<a id="source-ctg-observation-nct01304511-2024-04-03-78215f11e840"></a>
- **ClinicalTrials.gov record NCT01304511 · retained source version 2024-04-03:78215f11e84035913612808e5511b2583b6b27b7b62d943aa6993fb597acd138** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01304511) (`ctg-observation-nct01304511-2024-04-03-78215f11e840`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01304511." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct01304511-ganirelix-v1 SHA-256: 6f93da6eb617d477353c7abd16ca49048010fdabc40667978deb078c336b82dc.

---

<a id="clinicaltrials-gov-nct01645241-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT01645241

> PeptideScanner retained ClinicalTrials.gov record NCT01645241 at 2026-11-15T22:03:26.540Z. Its registry update date was 2014-10-27, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct01645241-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-10-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01645241-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct01645241-ganirelix-v1
- Content SHA-256: `452a1a8f1f89acf7f34dbab79f024812205363e036795c589fcaf000d8874dc9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01645241 ([`ctg-observation-nct01645241-2014-10-27-842905b4b3f3`](#source-ctg-observation-nct01645241-2014-10-27-842905b4b3f3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01645241 at 2026-11-15T22:03:26.540Z. Its registry update date was 2014-10-27, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct01645241-2014-10-27-842905b4b3f3`](#source-ctg-observation-nct01645241-2014-10-27-842905b4b3f3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01645241 at 2026-11-15T22:03:26.540Z. Its registry update date was 2014-10-27, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct01645241-2014-10-27-842905b4b3f3`](#source-ctg-observation-nct01645241-2014-10-27-842905b4b3f3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01645241-2014-10-27-842905b4b3f3`](#source-ctg-observation-nct01645241-2014-10-27-842905b4b3f3))

### Sources

<a id="source-ctg-observation-nct01645241-2014-10-27-842905b4b3f3"></a>
- **ClinicalTrials.gov record NCT01645241 · retained source version 2014-10-27:842905b4b3f3ed283887f88ca3d0f67df25cbbcc0e42a9afc90a1aa99144181a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01645241) (`ctg-observation-nct01645241-2014-10-27-842905b4b3f3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01645241." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct01645241-ganirelix-v1 SHA-256: 452a1a8f1f89acf7f34dbab79f024812205363e036795c589fcaf000d8874dc9.

---

<a id="clinicaltrials-gov-nct01816321-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT01816321

> PeptideScanner retained ClinicalTrials.gov record NCT01816321 at 2026-11-15T22:03:26.540Z. Its registry update date was 2016-06-23, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct01816321-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-06-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01816321-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct01816321-ganirelix-v1
- Content SHA-256: `988faba406cd7d78ee367d20cc61de269027ffe249931e8e85d0c2b04f57e466`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01816321 ([`ctg-observation-nct01816321-2016-06-23-374c808d980b`](#source-ctg-observation-nct01816321-2016-06-23-374c808d980b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01816321 at 2026-11-15T22:03:26.540Z. Its registry update date was 2016-06-23, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct01816321-2016-06-23-374c808d980b`](#source-ctg-observation-nct01816321-2016-06-23-374c808d980b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01816321 at 2026-11-15T22:03:26.540Z. Its registry update date was 2016-06-23, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct01816321-2016-06-23-374c808d980b`](#source-ctg-observation-nct01816321-2016-06-23-374c808d980b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01816321-2016-06-23-374c808d980b`](#source-ctg-observation-nct01816321-2016-06-23-374c808d980b))

### Sources

<a id="source-ctg-observation-nct01816321-2016-06-23-374c808d980b"></a>
- **ClinicalTrials.gov record NCT01816321 · retained source version 2016-06-23:374c808d980b59488b7bebcd5798c7e70caaf63876f3335ba279297efd1501cf** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01816321) (`ctg-observation-nct01816321-2016-06-23-374c808d980b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01816321." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct01816321-ganirelix-v1 SHA-256: 988faba406cd7d78ee367d20cc61de269027ffe249931e8e85d0c2b04f57e466.

---

<a id="clinicaltrials-gov-nct03051087-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT03051087

> PeptideScanner retained ClinicalTrials.gov record NCT03051087 at 2026-11-15T22:03:26.540Z. Its registry update date was 2019-07-02, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct03051087-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-07-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03051087-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct03051087-ganirelix-v1
- Content SHA-256: `3b74b2c34727ca3fb4a501d56a5f6302221bbb54f502f77a72f29aa9d57bb3e8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03051087 ([`ctg-observation-nct03051087-2019-07-02-62a3d0a37109`](#source-ctg-observation-nct03051087-2019-07-02-62a3d0a37109))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03051087 at 2026-11-15T22:03:26.540Z. Its registry update date was 2019-07-02, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct03051087-2019-07-02-62a3d0a37109`](#source-ctg-observation-nct03051087-2019-07-02-62a3d0a37109))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03051087 at 2026-11-15T22:03:26.540Z. Its registry update date was 2019-07-02, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct03051087-2019-07-02-62a3d0a37109`](#source-ctg-observation-nct03051087-2019-07-02-62a3d0a37109))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03051087-2019-07-02-62a3d0a37109`](#source-ctg-observation-nct03051087-2019-07-02-62a3d0a37109))

### Sources

<a id="source-ctg-observation-nct03051087-2019-07-02-62a3d0a37109"></a>
- **ClinicalTrials.gov record NCT03051087 · retained source version 2019-07-02:62a3d0a371098703fc11b0c655eb71f4ebe75d5df7ca484c273d5e16999a822f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03051087) (`ctg-observation-nct03051087-2019-07-02-62a3d0a37109`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03051087." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct03051087-ganirelix-v1 SHA-256: 3b74b2c34727ca3fb4a501d56a5f6302221bbb54f502f77a72f29aa9d57bb3e8.

---

<a id="clinicaltrials-gov-nct03142893-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT03142893

> PeptideScanner retained ClinicalTrials.gov record NCT03142893 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct03142893-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-09-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03142893-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct03142893-ganirelix-v1
- Content SHA-256: `dba7af418041eef6645cd0ad9316469f82d7b1d054a69a836ee203de13370fb1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03142893 ([`ctg-observation-nct03142893-2025-09-11-bcb88b00dd17`](#source-ctg-observation-nct03142893-2025-09-11-bcb88b00dd17))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03142893 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct03142893-2025-09-11-bcb88b00dd17`](#source-ctg-observation-nct03142893-2025-09-11-bcb88b00dd17))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03142893 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct03142893-2025-09-11-bcb88b00dd17`](#source-ctg-observation-nct03142893-2025-09-11-bcb88b00dd17))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03142893-2025-09-11-bcb88b00dd17`](#source-ctg-observation-nct03142893-2025-09-11-bcb88b00dd17))

### Sources

<a id="source-ctg-observation-nct03142893-2025-09-11-bcb88b00dd17"></a>
- **ClinicalTrials.gov record NCT03142893 · retained source version 2025-09-11:bcb88b00dd17f057c0d9b3d93fe9094992fbad52c4e2f60644e1072f447ff349** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03142893) (`ctg-observation-nct03142893-2025-09-11-bcb88b00dd17`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03142893." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct03142893-ganirelix-v1 SHA-256: dba7af418041eef6645cd0ad9316469f82d7b1d054a69a836ee203de13370fb1.

---

<a id="clinicaltrials-gov-nct03300518-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT03300518

> PeptideScanner retained ClinicalTrials.gov record NCT03300518 at 2026-11-15T22:03:26.540Z. Its registry update date was 2022-01-11, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct03300518-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-01-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03300518-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct03300518-ganirelix-v1
- Content SHA-256: `a01e1fa11c9acdecc710ca531f0c1fc21db596cd733a74350dd51627b4deaf54`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03300518 ([`ctg-observation-nct03300518-2022-01-11-c2472a036c0c`](#source-ctg-observation-nct03300518-2022-01-11-c2472a036c0c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03300518 at 2026-11-15T22:03:26.540Z. Its registry update date was 2022-01-11, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct03300518-2022-01-11-c2472a036c0c`](#source-ctg-observation-nct03300518-2022-01-11-c2472a036c0c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03300518 at 2026-11-15T22:03:26.540Z. Its registry update date was 2022-01-11, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct03300518-2022-01-11-c2472a036c0c`](#source-ctg-observation-nct03300518-2022-01-11-c2472a036c0c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03300518-2022-01-11-c2472a036c0c`](#source-ctg-observation-nct03300518-2022-01-11-c2472a036c0c))

### Sources

<a id="source-ctg-observation-nct03300518-2022-01-11-c2472a036c0c"></a>
- **ClinicalTrials.gov record NCT03300518 · retained source version 2022-01-11:c2472a036c0c6354c6fc256c378c4e7efc9dddb11f443d2a571740eb45c13403** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03300518) (`ctg-observation-nct03300518-2022-01-11-c2472a036c0c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03300518." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct03300518-ganirelix-v1 SHA-256: a01e1fa11c9acdecc710ca531f0c1fc21db596cd733a74350dd51627b4deaf54.

---

<a id="clinicaltrials-gov-nct04037605-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT04037605

> PeptideScanner retained ClinicalTrials.gov record NCT04037605 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct04037605-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-09-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04037605-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct04037605-ganirelix-v1
- Content SHA-256: `7360aa7d8492e4f8dc04466a5752275f3dd89ed722b8771b5fa6878ab7cf1be7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04037605 ([`ctg-observation-nct04037605-2025-09-11-6d20257188ba`](#source-ctg-observation-nct04037605-2025-09-11-6d20257188ba))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04037605 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct04037605-2025-09-11-6d20257188ba`](#source-ctg-observation-nct04037605-2025-09-11-6d20257188ba))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04037605 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct04037605-2025-09-11-6d20257188ba`](#source-ctg-observation-nct04037605-2025-09-11-6d20257188ba))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04037605-2025-09-11-6d20257188ba`](#source-ctg-observation-nct04037605-2025-09-11-6d20257188ba))

### Sources

<a id="source-ctg-observation-nct04037605-2025-09-11-6d20257188ba"></a>
- **ClinicalTrials.gov record NCT04037605 · retained source version 2025-09-11:6d20257188ba033ee3fb94068bee4b0405b2a61ad4853def052b5d372ce90cdb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04037605) (`ctg-observation-nct04037605-2025-09-11-6d20257188ba`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04037605." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct04037605-ganirelix-v1 SHA-256: 7360aa7d8492e4f8dc04466a5752275f3dd89ed722b8771b5fa6878ab7cf1be7.

---

<a id="clinicaltrials-gov-nct05751252-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT05751252

> PeptideScanner retained ClinicalTrials.gov record NCT05751252 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct05751252-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-04-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05751252-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct05751252-ganirelix-v1
- Content SHA-256: `d4417b007810a6c0ae1e487ff0269888d37466ebebfa8650fc0345368082fdd1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05751252 ([`ctg-observation-nct05751252-2025-04-27-eb4f14304100`](#source-ctg-observation-nct05751252-2025-04-27-eb4f14304100))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05751252 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct05751252-2025-04-27-eb4f14304100`](#source-ctg-observation-nct05751252-2025-04-27-eb4f14304100))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05751252 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct05751252-2025-04-27-eb4f14304100`](#source-ctg-observation-nct05751252-2025-04-27-eb4f14304100))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05751252-2025-04-27-eb4f14304100`](#source-ctg-observation-nct05751252-2025-04-27-eb4f14304100))

### Sources

<a id="source-ctg-observation-nct05751252-2025-04-27-eb4f14304100"></a>
- **ClinicalTrials.gov record NCT05751252 · retained source version 2025-04-27:eb4f14304100bace126234cf2c87f24635ab7fd95b4bfb8a0a0f82a6e3836588** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05751252) (`ctg-observation-nct05751252-2025-04-27-eb4f14304100`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05751252." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct05751252-ganirelix-v1 SHA-256: d4417b007810a6c0ae1e487ff0269888d37466ebebfa8650fc0345368082fdd1.

---

<a id="clinicaltrials-gov-nct05954962-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT05954962

> PeptideScanner retained ClinicalTrials.gov record NCT05954962 at 2026-11-15T22:03:26.540Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct05954962-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05954962-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct05954962-ganirelix-v1
- Content SHA-256: `3cc190083c441896b8c5bec8de66d349eaa59bc44ac966fb244b1b726cb36d5c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05954962 ([`ctg-observation-nct05954962-2026-03-27-f6a81d4a5f5d`](#source-ctg-observation-nct05954962-2026-03-27-f6a81d4a5f5d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05954962 at 2026-11-15T22:03:26.540Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct05954962-2026-03-27-f6a81d4a5f5d`](#source-ctg-observation-nct05954962-2026-03-27-f6a81d4a5f5d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05954962 at 2026-11-15T22:03:26.540Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct05954962-2026-03-27-f6a81d4a5f5d`](#source-ctg-observation-nct05954962-2026-03-27-f6a81d4a5f5d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05954962-2026-03-27-f6a81d4a5f5d`](#source-ctg-observation-nct05954962-2026-03-27-f6a81d4a5f5d))

### Sources

<a id="source-ctg-observation-nct05954962-2026-03-27-f6a81d4a5f5d"></a>
- **ClinicalTrials.gov record NCT05954962 · retained source version 2026-03-27:f6a81d4a5f5dc6ff5281c3904cd77ba218862719f7887ff2c9cccedd0bb6d0ca** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05954962) (`ctg-observation-nct05954962-2026-03-27-f6a81d4a5f5d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05954962." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct05954962-ganirelix-v1 SHA-256: 3cc190083c441896b8c5bec8de66d349eaa59bc44ac966fb244b1b726cb36d5c.

---

<a id="clinicaltrials-gov-nct06091436-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT06091436

> PeptideScanner retained ClinicalTrials.gov record NCT06091436 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-12-03, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct06091436-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-12-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06091436-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct06091436-ganirelix-v1
- Content SHA-256: `88d6cff52a7789b78ecfe96988cd4c1ad90f22079ab3c8680e1d07d86350261c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06091436 ([`ctg-observation-nct06091436-2024-12-03-aff6d5ddd60f`](#source-ctg-observation-nct06091436-2024-12-03-aff6d5ddd60f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06091436 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-12-03, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct06091436-2024-12-03-aff6d5ddd60f`](#source-ctg-observation-nct06091436-2024-12-03-aff6d5ddd60f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06091436 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-12-03, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct06091436-2024-12-03-aff6d5ddd60f`](#source-ctg-observation-nct06091436-2024-12-03-aff6d5ddd60f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06091436-2024-12-03-aff6d5ddd60f`](#source-ctg-observation-nct06091436-2024-12-03-aff6d5ddd60f))

### Sources

<a id="source-ctg-observation-nct06091436-2024-12-03-aff6d5ddd60f"></a>
- **ClinicalTrials.gov record NCT06091436 · retained source version 2024-12-03:aff6d5ddd60f91183cf2dac02d4d8730073b36d572409fce111f8b1d8a6656f9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06091436) (`ctg-observation-nct06091436-2024-12-03-aff6d5ddd60f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06091436." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct06091436-ganirelix-v1 SHA-256: 88d6cff52a7789b78ecfe96988cd4c1ad90f22079ab3c8680e1d07d86350261c.

---

<a id="clinicaltrials-gov-nct06745466-ganirelix-v1"></a>

## ClinicalTrials.gov record NCT06745466

> PeptideScanner retained ClinicalTrials.gov record NCT06745466 at 2026-11-15T22:03:26.540Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was ganirelix.

- Evidence object: `story:clinicaltrials-gov-nct06745466-ganirelix:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06745466-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct06745466-ganirelix-v1
- Content SHA-256: `c13cefd94a4bc5313d5892a16fa31b68452948b57e3a7fa2ae9fcf17ab971816`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06745466 ([`ctg-observation-nct06745466-2026-07-02-d0900b6efd7f`](#source-ctg-observation-nct06745466-2026-07-02-d0900b6efd7f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06745466 at 2026-11-15T22:03:26.540Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct06745466-2026-07-02-d0900b6efd7f`](#source-ctg-observation-nct06745466-2026-07-02-d0900b6efd7f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06745466 at 2026-11-15T22:03:26.540Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was ganirelix. ([`ctg-observation-nct06745466-2026-07-02-d0900b6efd7f`](#source-ctg-observation-nct06745466-2026-07-02-d0900b6efd7f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06745466-2026-07-02-d0900b6efd7f`](#source-ctg-observation-nct06745466-2026-07-02-d0900b6efd7f))

### Sources

<a id="source-ctg-observation-nct06745466-2026-07-02-d0900b6efd7f"></a>
- **ClinicalTrials.gov record NCT06745466 · retained source version 2026-07-02:d0900b6efd7f3dc53c396ff66722dbd28e34321e9474f054141a13a440411a90** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06745466) (`ctg-observation-nct06745466-2026-07-02-d0900b6efd7f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06745466." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#clinicaltrials-gov-nct06745466-ganirelix-v1 SHA-256: c13cefd94a4bc5313d5892a16fa31b68452948b57e3a7fa2ae9fcf17ab971816.

---

<a id="fda-drugs-anda204246-v1"></a>

## Drugs@FDA application ANDA204246

> The official Drugs@FDA dataset lists original submission 1 for ANDA 204246 with status AP dated 2018-11-30, and names ganirelix acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda204246:v1`
- Evidence domain: Regulatory
- Date in source: 2018-11-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda204246/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#fda-drugs-anda204246-v1
- Content SHA-256: `13c8d774b986865d321c04e83bf2b4505c2fb5ec1ec2e8982956ad1473d67a42`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA204246 ([`fda-drugs-anda204246-2018-11-30-02f75619b5fa`](#source-fda-drugs-anda204246-2018-11-30-02f75619b5fa))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 204246 with status AP dated 2018-11-30, and names ganirelix acetate among the application record's active ingredients. ([`fda-drugs-anda204246-2018-11-30-02f75619b5fa`](#source-fda-drugs-anda204246-2018-11-30-02f75619b5fa))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 204246 with status AP dated 2018-11-30, and names ganirelix acetate among the application record's active ingredients. ([`fda-drugs-anda204246-2018-11-30-02f75619b5fa`](#source-fda-drugs-anda204246-2018-11-30-02f75619b5fa))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda204246-2018-11-30-02f75619b5fa`](#source-fda-drugs-anda204246-2018-11-30-02f75619b5fa))

### Sources

<a id="source-fda-drugs-anda204246-2018-11-30-02f75619b5fa"></a>
- **Drugs@FDA application ANDA204246 · original submission status AP · 2018-11-30 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA204246%22&limit=1) (`fda-drugs-anda204246-2018-11-30-02f75619b5fa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA204246." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#fda-drugs-anda204246-v1 SHA-256: 13c8d774b986865d321c04e83bf2b4505c2fb5ec1ec2e8982956ad1473d67a42.

---

<a id="fda-drugs-anda212613-v1"></a>

## Drugs@FDA application ANDA212613

> The official Drugs@FDA dataset lists original submission 1 for ANDA 212613 with status AP dated 2022-04-07, and names ganirelix acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda212613:v1`
- Evidence domain: Regulatory
- Date in source: 2022-04-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda212613/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#fda-drugs-anda212613-v1
- Content SHA-256: `ecca14297f96a1365400fcf2c66871b237c48f4e79de38a8be76194c96a7d02c`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA212613 ([`fda-drugs-anda212613-2022-04-07-5fa8adaad20a`](#source-fda-drugs-anda212613-2022-04-07-5fa8adaad20a))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 212613 with status AP dated 2022-04-07, and names ganirelix acetate among the application record's active ingredients. ([`fda-drugs-anda212613-2022-04-07-5fa8adaad20a`](#source-fda-drugs-anda212613-2022-04-07-5fa8adaad20a))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 212613 with status AP dated 2022-04-07, and names ganirelix acetate among the application record's active ingredients. ([`fda-drugs-anda212613-2022-04-07-5fa8adaad20a`](#source-fda-drugs-anda212613-2022-04-07-5fa8adaad20a))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda212613-2022-04-07-5fa8adaad20a`](#source-fda-drugs-anda212613-2022-04-07-5fa8adaad20a))

### Sources

<a id="source-fda-drugs-anda212613-2022-04-07-5fa8adaad20a"></a>
- **Drugs@FDA application ANDA212613 · original submission status AP · 2022-04-07 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA212613%22&limit=1) (`fda-drugs-anda212613-2022-04-07-5fa8adaad20a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA212613." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#fda-drugs-anda212613-v1 SHA-256: ecca14297f96a1365400fcf2c66871b237c48f4e79de38a8be76194c96a7d02c.

---

<a id="fda-drugs-anda214996-v1"></a>

## Drugs@FDA application ANDA214996

> The official Drugs@FDA dataset lists original submission 1 for ANDA 214996 with status AP dated 2022-06-06, and names ganirelix acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda214996:v1`
- Evidence domain: Regulatory
- Date in source: 2022-06-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda214996/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#fda-drugs-anda214996-v1
- Content SHA-256: `c64a183a70a8628791e936ab69f658caa1515a8e2da6eae50f1611fa58972c32`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA214996 ([`fda-drugs-anda214996-2022-06-06-547035b9c429`](#source-fda-drugs-anda214996-2022-06-06-547035b9c429))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 214996 with status AP dated 2022-06-06, and names ganirelix acetate among the application record's active ingredients. ([`fda-drugs-anda214996-2022-06-06-547035b9c429`](#source-fda-drugs-anda214996-2022-06-06-547035b9c429))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 214996 with status AP dated 2022-06-06, and names ganirelix acetate among the application record's active ingredients. ([`fda-drugs-anda214996-2022-06-06-547035b9c429`](#source-fda-drugs-anda214996-2022-06-06-547035b9c429))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda214996-2022-06-06-547035b9c429`](#source-fda-drugs-anda214996-2022-06-06-547035b9c429))

### Sources

<a id="source-fda-drugs-anda214996-2022-06-06-547035b9c429"></a>
- **Drugs@FDA application ANDA214996 · original submission status AP · 2022-06-06 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA214996%22&limit=1) (`fda-drugs-anda214996-2022-06-06-547035b9c429`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA214996." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#fda-drugs-anda214996-v1 SHA-256: c64a183a70a8628791e936ab69f658caa1515a8e2da6eae50f1611fa58972c32.

---

<a id="fda-drugs-anda215658-v1"></a>

## Drugs@FDA application ANDA215658

> The official Drugs@FDA dataset lists original submission 1 for ANDA 215658 with status AP dated 2023-02-28, and names ganirelix acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda215658:v1`
- Evidence domain: Regulatory
- Date in source: 2023-02-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda215658/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#fda-drugs-anda215658-v1
- Content SHA-256: `d13890ee18ec468f35115264c58456c65db9b8c898eaef9fb58d6af05d721433`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA215658 ([`fda-drugs-anda215658-2023-02-28-d40cd57f2c52`](#source-fda-drugs-anda215658-2023-02-28-d40cd57f2c52))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 215658 with status AP dated 2023-02-28, and names ganirelix acetate among the application record's active ingredients. ([`fda-drugs-anda215658-2023-02-28-d40cd57f2c52`](#source-fda-drugs-anda215658-2023-02-28-d40cd57f2c52))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 215658 with status AP dated 2023-02-28, and names ganirelix acetate among the application record's active ingredients. ([`fda-drugs-anda215658-2023-02-28-d40cd57f2c52`](#source-fda-drugs-anda215658-2023-02-28-d40cd57f2c52))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda215658-2023-02-28-d40cd57f2c52`](#source-fda-drugs-anda215658-2023-02-28-d40cd57f2c52))

### Sources

<a id="source-fda-drugs-anda215658-2023-02-28-d40cd57f2c52"></a>
- **Drugs@FDA application ANDA215658 · original submission status AP · 2023-02-28 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA215658%22&limit=1) (`fda-drugs-anda215658-2023-02-28-d40cd57f2c52`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA215658." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#fda-drugs-anda215658-v1 SHA-256: d13890ee18ec468f35115264c58456c65db9b8c898eaef9fb58d6af05d721433.

---

<a id="fda-drugs-anda216075-v1"></a>

## Drugs@FDA application ANDA216075

> The official Drugs@FDA dataset lists original submission 1 for ANDA 216075 with status AP dated 2023-11-16, and names ganirelix acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda216075:v1`
- Evidence domain: Regulatory
- Date in source: 2023-11-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda216075/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#fda-drugs-anda216075-v1
- Content SHA-256: `9a907c592c1f3098c8937d05e28b4832ca8c3737949d23def1c9def6252ea6a3`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA216075 ([`fda-drugs-anda216075-2023-11-16-d8b86343b7e8`](#source-fda-drugs-anda216075-2023-11-16-d8b86343b7e8))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 216075 with status AP dated 2023-11-16, and names ganirelix acetate among the application record's active ingredients. ([`fda-drugs-anda216075-2023-11-16-d8b86343b7e8`](#source-fda-drugs-anda216075-2023-11-16-d8b86343b7e8))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 216075 with status AP dated 2023-11-16, and names ganirelix acetate among the application record's active ingredients. ([`fda-drugs-anda216075-2023-11-16-d8b86343b7e8`](#source-fda-drugs-anda216075-2023-11-16-d8b86343b7e8))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda216075-2023-11-16-d8b86343b7e8`](#source-fda-drugs-anda216075-2023-11-16-d8b86343b7e8))

### Sources

<a id="source-fda-drugs-anda216075-2023-11-16-d8b86343b7e8"></a>
- **Drugs@FDA application ANDA216075 · original submission status AP · 2023-11-16 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA216075%22&limit=1) (`fda-drugs-anda216075-2023-11-16-d8b86343b7e8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA216075." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#fda-drugs-anda216075-v1 SHA-256: 9a907c592c1f3098c8937d05e28b4832ca8c3737949d23def1c9def6252ea6a3.

---

<a id="fda-drugs-anda218855-v1"></a>

## Drugs@FDA application ANDA218855

> The official Drugs@FDA dataset lists original submission 1 for ANDA 218855 with status AP dated 2025-04-23, and names ganirelix acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda218855:v1`
- Evidence domain: Regulatory
- Date in source: 2025-04-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda218855/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#fda-drugs-anda218855-v1
- Content SHA-256: `1f4733a802e5c93ea08bec34844785662afb4065ff39b2801a9e42c02a3b5c4b`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA218855 ([`fda-drugs-anda218855-2025-04-23-bcbf9a9482d7`](#source-fda-drugs-anda218855-2025-04-23-bcbf9a9482d7))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 218855 with status AP dated 2025-04-23, and names ganirelix acetate among the application record's active ingredients. ([`fda-drugs-anda218855-2025-04-23-bcbf9a9482d7`](#source-fda-drugs-anda218855-2025-04-23-bcbf9a9482d7))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 218855 with status AP dated 2025-04-23, and names ganirelix acetate among the application record's active ingredients. ([`fda-drugs-anda218855-2025-04-23-bcbf9a9482d7`](#source-fda-drugs-anda218855-2025-04-23-bcbf9a9482d7))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda218855-2025-04-23-bcbf9a9482d7`](#source-fda-drugs-anda218855-2025-04-23-bcbf9a9482d7))

### Sources

<a id="source-fda-drugs-anda218855-2025-04-23-bcbf9a9482d7"></a>
- **Drugs@FDA application ANDA218855 · original submission status AP · 2025-04-23 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA218855%22&limit=1) (`fda-drugs-anda218855-2025-04-23-bcbf9a9482d7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA218855." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#fda-drugs-anda218855-v1 SHA-256: 1f4733a802e5c93ea08bec34844785662afb4065ff39b2801a9e42c02a3b5c4b.

---

<a id="fda-drugs-anda219454-v1"></a>

## Drugs@FDA application ANDA219454

> The official Drugs@FDA dataset lists original submission 1 for ANDA 219454 with status AP dated 2025-06-27, and names ganirelix acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda219454:v1`
- Evidence domain: Regulatory
- Date in source: 2025-06-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda219454/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#fda-drugs-anda219454-v1
- Content SHA-256: `b3da6cb3afa0ebcecd47938391881eefb6dcb39a5a7b62e399a08301e53c7ac0`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA219454 ([`fda-drugs-anda219454-2025-06-27-9ef446784e48`](#source-fda-drugs-anda219454-2025-06-27-9ef446784e48))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 219454 with status AP dated 2025-06-27, and names ganirelix acetate among the application record's active ingredients. ([`fda-drugs-anda219454-2025-06-27-9ef446784e48`](#source-fda-drugs-anda219454-2025-06-27-9ef446784e48))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 219454 with status AP dated 2025-06-27, and names ganirelix acetate among the application record's active ingredients. ([`fda-drugs-anda219454-2025-06-27-9ef446784e48`](#source-fda-drugs-anda219454-2025-06-27-9ef446784e48))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda219454-2025-06-27-9ef446784e48`](#source-fda-drugs-anda219454-2025-06-27-9ef446784e48))

### Sources

<a id="source-fda-drugs-anda219454-2025-06-27-9ef446784e48"></a>
- **Drugs@FDA application ANDA219454 · original submission status AP · 2025-06-27 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA219454%22&limit=1) (`fda-drugs-anda219454-2025-06-27-9ef446784e48`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA219454." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#fda-drugs-anda219454-v1 SHA-256: b3da6cb3afa0ebcecd47938391881eefb6dcb39a5a7b62e399a08301e53c7ac0.

---

<a id="fda-drugs-nda021057-v1"></a>

## Drugs@FDA application NDA021057

> The official Drugs@FDA dataset lists original submission 1 for NDA 021057 with status AP dated 1999-07-29, and names ganirelix acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda021057:v1`
- Evidence domain: Regulatory
- Date in source: 1999-07-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda021057/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#fda-drugs-nda021057-v1
- Content SHA-256: `a67573f53218f45046691160e1a7654e04dc47c285a05313d2882c3368db43df`

### Claims and source pins

#### Headline

Drugs@FDA application NDA021057 ([`fda-drugs-nda021057-1999-07-29-a71b3f54a1d4`](#source-fda-drugs-nda021057-1999-07-29-a71b3f54a1d4))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 021057 with status AP dated 1999-07-29, and names ganirelix acetate among the application record's active ingredients. ([`fda-drugs-nda021057-1999-07-29-a71b3f54a1d4`](#source-fda-drugs-nda021057-1999-07-29-a71b3f54a1d4))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 021057 with status AP dated 1999-07-29, and names ganirelix acetate among the application record's active ingredients. ([`fda-drugs-nda021057-1999-07-29-a71b3f54a1d4`](#source-fda-drugs-nda021057-1999-07-29-a71b3f54a1d4))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda021057-1999-07-29-a71b3f54a1d4`](#source-fda-drugs-nda021057-1999-07-29-a71b3f54a1d4))

### Sources

<a id="source-fda-drugs-nda021057-1999-07-29-a71b3f54a1d4"></a>
- **Drugs@FDA application NDA021057 · original submission status AP · 1999-07-29 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021057%22&limit=1) (`fda-drugs-nda021057-1999-07-29-a71b3f54a1d4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA021057." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#fda-drugs-nda021057-v1 SHA-256: a67573f53218f45046691160e1a7654e04dc47c285a05313d2882c3368db43df.

---

<a id="federal-register-04-24378-v1"></a>

## Federal Register notice 04-24378

> The Federal Register published notice 04-24378, attributed to FDA and its parent HHS department, on 2004-11-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; GANIRELIX ACETATE INJECTION (Formerly ANTAGON),” and PeptideScanner's exact reviewed identity mapping connects the document to Ganirelix.

- Evidence object: `story:federal-register-04-24378:v1`
- Evidence domain: Regulatory
- Date in source: 2004-11-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-04-24378/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#federal-register-04-24378-v1
- Content SHA-256: `343719fc25b3a8a15aaf0828f8bcdabf9e8ecc8b02990bf7c715ccc6060ada4c`

### Claims and source pins

#### Headline

Federal Register notice 04-24378 ([`federal-register-04-24378-fa6fd1e78a8a`](#source-federal-register-04-24378-fa6fd1e78a8a))

#### Summary

The Federal Register published notice 04-24378, attributed to FDA and its parent HHS department, on 2004-11-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; GANIRELIX ACETATE INJECTION (Formerly ANTAGON),” and PeptideScanner's exact reviewed identity mapping connects the document to Ganirelix. ([`federal-register-04-24378-fa6fd1e78a8a`](#source-federal-register-04-24378-fa6fd1e78a8a))

#### Paragraph 1

The Federal Register published notice 04-24378, attributed to FDA and its parent HHS department, on 2004-11-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; GANIRELIX ACETATE INJECTION (Formerly ANTAGON),” and PeptideScanner's exact reviewed identity mapping connects the document to Ganirelix. ([`federal-register-04-24378-fa6fd1e78a8a`](#source-federal-register-04-24378-fa6fd1e78a8a))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-04-24378-fa6fd1e78a8a`](#source-federal-register-04-24378-fa6fd1e78a8a))

### Sources

<a id="source-federal-register-04-24378-fa6fd1e78a8a"></a>
- **Federal Register notice 04-24378 · published 2004-11-02 · Determination of Regulatory Review Period for Purposes of Patent Extension; GANIRELIX ACETATE INJECTION (Formerly ANTAGON)** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2004-11-02/pdf/04-24378.pdf) (`federal-register-04-24378-fa6fd1e78a8a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 04-24378." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#federal-register-04-24378-v1 SHA-256: 343719fc25b3a8a15aaf0828f8bcdabf9e8ecc8b02990bf7c715ccc6060ada4c.

---

<a id="pubmed-pmid-10582819-ganirelix-v1"></a>

## Ganirelix acetate.

> PubMed lists PMID 10582819 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 1999-11-15 (day precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-10582819-ganirelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-02-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-10582819-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#pubmed-pmid-10582819-ganirelix-v1
- Content SHA-256: `10129d9a4d88a33601e034b0645436a4c85168baeb2fb5aeb0319d33c1e852f2`

### Claims and source pins

#### Headline

Ganirelix acetate. ([`pubmed-observation-pmid-10582819-2019-02-21-706cc62fa436`](#source-pubmed-observation-pmid-10582819-2019-02-21-706cc62fa436))

#### Summary

PubMed lists PMID 10582819 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 1999-11-15 (day precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10582819-2019-02-21-706cc62fa436`](#source-pubmed-observation-pmid-10582819-2019-02-21-706cc62fa436))

#### Paragraph 1

PubMed lists PMID 10582819 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 1999-11-15 (day precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10582819-2019-02-21-706cc62fa436`](#source-pubmed-observation-pmid-10582819-2019-02-21-706cc62fa436))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-10582819-2019-02-21-706cc62fa436`](#source-pubmed-observation-pmid-10582819-2019-02-21-706cc62fa436))

### Sources

<a id="source-pubmed-observation-pmid-10582819-2019-02-21-706cc62fa436"></a>
- **Ganirelix acetate. · retained source version 1:2019-02-21:current:706cc62fa436536b7927a0180248bc234cfa37774d5bf5a3115adf69f3b4c9db** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/10582819/) (`pubmed-observation-pmid-10582819-2019-02-21-706cc62fa436`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Ganirelix acetate." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#pubmed-pmid-10582819-ganirelix-v1 SHA-256: 10129d9a4d88a33601e034b0645436a4c85168baeb2fb5aeb0319d33c1e852f2.

---

<a id="pubmed-pmid-10718102-ganirelix-v1"></a>

## Ganirelix.

> PubMed lists PMID 10718102 in Drugs as Journal Article, Review, with publication-date metadata of 2000-01 (month precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-10718102-ganirelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-10718102-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#pubmed-pmid-10718102-ganirelix-v1
- Content SHA-256: `ef5a64a177629e9f05e752d92535882719c5ae514b5642f527538666199f0a3e`

### Claims and source pins

#### Headline

Ganirelix. ([`pubmed-observation-pmid-10718102-2018-11-13-41ff322a2392`](#source-pubmed-observation-pmid-10718102-2018-11-13-41ff322a2392))

#### Summary

PubMed lists PMID 10718102 in Drugs as Journal Article, Review, with publication-date metadata of 2000-01 (month precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10718102-2018-11-13-41ff322a2392`](#source-pubmed-observation-pmid-10718102-2018-11-13-41ff322a2392))

#### Paragraph 1

PubMed lists PMID 10718102 in Drugs as Journal Article, Review, with publication-date metadata of 2000-01 (month precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10718102-2018-11-13-41ff322a2392`](#source-pubmed-observation-pmid-10718102-2018-11-13-41ff322a2392))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-10718102-2018-11-13-41ff322a2392`](#source-pubmed-observation-pmid-10718102-2018-11-13-41ff322a2392))

### Sources

<a id="source-pubmed-observation-pmid-10718102-2018-11-13-41ff322a2392"></a>
- **Ganirelix. · retained source version 1:2018-11-13:current:41ff322a2392f626f98bb8004b8952dd3df01489da2a33c340dd5b9c2d339d8a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/10718102/) (`pubmed-observation-pmid-10718102-2018-11-13-41ff322a2392`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Ganirelix." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#pubmed-pmid-10718102-ganirelix-v1 SHA-256: ef5a64a177629e9f05e752d92535882719c5ae514b5642f527538666199f0a3e.

---

<a id="pubmed-pmid-20504085-ganirelix-v1"></a>

## Ganirelix for luteolysis in poor responder patients undergoing IVF treatment: a Scandinavian multicenter 'extended pilot study'.

> PubMed lists PMID 20504085 in Acta obstetricia et gynecologica Scandinavica as Journal Article, Multicenter Study, with publication-date metadata of 2010-06 (month precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20504085-ganirelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20504085-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#pubmed-pmid-20504085-ganirelix-v1
- Content SHA-256: `79beeaa42d3d52714dc73d048a3035f666a30f2ee7f8d5ceb7a3251fedf3e7f3`

### Claims and source pins

#### Headline

Ganirelix for luteolysis in poor responder patients undergoing IVF treatment: a Scandinavian multicenter 'extended pilot study'. ([`pubmed-observation-pmid-20504085-2016-11-25-38b215f010b6`](#source-pubmed-observation-pmid-20504085-2016-11-25-38b215f010b6))

#### Summary

PubMed lists PMID 20504085 in Acta obstetricia et gynecologica Scandinavica as Journal Article, Multicenter Study, with publication-date metadata of 2010-06 (month precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20504085-2016-11-25-38b215f010b6`](#source-pubmed-observation-pmid-20504085-2016-11-25-38b215f010b6))

#### Paragraph 1

PubMed lists PMID 20504085 in Acta obstetricia et gynecologica Scandinavica as Journal Article, Multicenter Study, with publication-date metadata of 2010-06 (month precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20504085-2016-11-25-38b215f010b6`](#source-pubmed-observation-pmid-20504085-2016-11-25-38b215f010b6))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20504085-2016-11-25-38b215f010b6`](#source-pubmed-observation-pmid-20504085-2016-11-25-38b215f010b6))

### Sources

<a id="source-pubmed-observation-pmid-20504085-2016-11-25-38b215f010b6"></a>
- **Ganirelix for luteolysis in poor responder patients undergoing IVF treatment: a Scandinavian multicenter 'extended pilot study'. · retained source version 1:2016-11-25:current:38b215f010b6be35ea850b6bdfe7185838b0dc9a33a77e21b46c49b2f775c5ba** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20504085/) (`pubmed-observation-pmid-20504085-2016-11-25-38b215f010b6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Ganirelix for luteolysis in poor responder patients undergoing IVF treatment: a Scandinavian multicenter 'extended pilot study'." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#pubmed-pmid-20504085-ganirelix-v1 SHA-256: 79beeaa42d3d52714dc73d048a3035f666a30f2ee7f8d5ceb7a3251fedf3e7f3.

---

<a id="pubmed-pmid-28721542-ganirelix-v1"></a>

## Molecular characterization, modeling, in silico analysis of equine pituitary gonadotropin alpha subunit and docking interaction studies with ganirelix.

> PubMed lists PMID 28721542 in In silico pharmacology as Journal Article, with publication-date metadata of 2017-07-18 (day precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28721542-ganirelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-03-26
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28721542-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#pubmed-pmid-28721542-ganirelix-v1
- Content SHA-256: `d74f9d357053533dce23173355940822cb4028b871016e385babf9dd4cbb879a`

### Claims and source pins

#### Headline

Molecular characterization, modeling, in silico analysis of equine pituitary gonadotropin alpha subunit and docking interaction studies with ganirelix. ([`pubmed-observation-pmid-28721542-2024-03-26-a04c34ec8aff`](#source-pubmed-observation-pmid-28721542-2024-03-26-a04c34ec8aff))

#### Summary

PubMed lists PMID 28721542 in In silico pharmacology as Journal Article, with publication-date metadata of 2017-07-18 (day precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28721542-2024-03-26-a04c34ec8aff`](#source-pubmed-observation-pmid-28721542-2024-03-26-a04c34ec8aff))

#### Paragraph 1

PubMed lists PMID 28721542 in In silico pharmacology as Journal Article, with publication-date metadata of 2017-07-18 (day precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28721542-2024-03-26-a04c34ec8aff`](#source-pubmed-observation-pmid-28721542-2024-03-26-a04c34ec8aff))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28721542-2024-03-26-a04c34ec8aff`](#source-pubmed-observation-pmid-28721542-2024-03-26-a04c34ec8aff))

### Sources

<a id="source-pubmed-observation-pmid-28721542-2024-03-26-a04c34ec8aff"></a>
- **Molecular characterization, modeling, in silico analysis of equine pituitary gonadotropin alpha subunit and docking interaction studies with ganirelix. · retained source version 1:2024-03-26:current:a04c34ec8affcc5a70d630e243b27e6c98becb38e6b0759b889392728a751c8d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28721542/) (`pubmed-observation-pmid-28721542-2024-03-26-a04c34ec8aff`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Molecular characterization, modeling, in silico analysis of equine pituitary gonadotropin alpha subunit and docking interaction studies with ganirelix." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#pubmed-pmid-28721542-ganirelix-v1 SHA-256: d74f9d357053533dce23173355940822cb4028b871016e385babf9dd4cbb879a.

---

<a id="pubmed-pmid-36279721-ganirelix-v1"></a>

## New local ganirelix sustained release therapy for uterine leiomyoma. Evaluation in a preclinical organ model.

> PubMed lists PMID 36279721 in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie as Journal Article, with publication-date metadata of 2022-10-21 (day precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36279721-ganirelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36279721-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#pubmed-pmid-36279721-ganirelix-v1
- Content SHA-256: `aaaaf35bb2a5d5f15f965b671142e418493c99cfaf8c28f6be05d398613a430c`

### Claims and source pins

#### Headline

New local ganirelix sustained release therapy for uterine leiomyoma. Evaluation in a preclinical organ model. ([`pubmed-observation-pmid-36279721-2026-01-27-ad0eccfae894`](#source-pubmed-observation-pmid-36279721-2026-01-27-ad0eccfae894))

#### Summary

PubMed lists PMID 36279721 in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie as Journal Article, with publication-date metadata of 2022-10-21 (day precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36279721-2026-01-27-ad0eccfae894`](#source-pubmed-observation-pmid-36279721-2026-01-27-ad0eccfae894))

#### Paragraph 1

PubMed lists PMID 36279721 in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie as Journal Article, with publication-date metadata of 2022-10-21 (day precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36279721-2026-01-27-ad0eccfae894`](#source-pubmed-observation-pmid-36279721-2026-01-27-ad0eccfae894))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36279721-2026-01-27-ad0eccfae894`](#source-pubmed-observation-pmid-36279721-2026-01-27-ad0eccfae894))

### Sources

<a id="source-pubmed-observation-pmid-36279721-2026-01-27-ad0eccfae894"></a>
- **New local ganirelix sustained release therapy for uterine leiomyoma. Evaluation in a preclinical organ model. · retained source version 1:2026-01-27:current:ad0eccfae894ff15474480ade22bbdabaf61d287e1ea0ba04bef6ab864eb05d9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36279721/) (`pubmed-observation-pmid-36279721-2026-01-27-ad0eccfae894`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "New local ganirelix sustained release therapy for uterine leiomyoma. Evaluation in a preclinical organ model." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#pubmed-pmid-36279721-ganirelix-v1 SHA-256: aaaaf35bb2a5d5f15f965b671142e418493c99cfaf8c28f6be05d398613a430c.

---

<a id="pubmed-pmid-8354719-ganirelix-v1"></a>

## Radioimmunoassay of ganirelix in plasma or serum.

> PubMed lists PMID 8354719 in Journal of immunoassay as Comparative Study, Journal Article, with publication-date metadata of 1993-09 (month precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-8354719-ganirelix:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8354719-ganirelix/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#pubmed-pmid-8354719-ganirelix-v1
- Content SHA-256: `f6e7573353139c56349a4379cec7b338e56597b9e2dba9ac07e2e064f41227a8`

### Claims and source pins

#### Headline

Radioimmunoassay of ganirelix in plasma or serum. ([`pubmed-observation-pmid-8354719-2019-11-01-5f6b2ab9fdb0`](#source-pubmed-observation-pmid-8354719-2019-11-01-5f6b2ab9fdb0))

#### Summary

PubMed lists PMID 8354719 in Journal of immunoassay as Comparative Study, Journal Article, with publication-date metadata of 1993-09 (month precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8354719-2019-11-01-5f6b2ab9fdb0`](#source-pubmed-observation-pmid-8354719-2019-11-01-5f6b2ab9fdb0))

#### Paragraph 1

PubMed lists PMID 8354719 in Journal of immunoassay as Comparative Study, Journal Article, with publication-date metadata of 1993-09 (month precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8354719-2019-11-01-5f6b2ab9fdb0`](#source-pubmed-observation-pmid-8354719-2019-11-01-5f6b2ab9fdb0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8354719-2019-11-01-5f6b2ab9fdb0`](#source-pubmed-observation-pmid-8354719-2019-11-01-5f6b2ab9fdb0))

### Sources

<a id="source-pubmed-observation-pmid-8354719-2019-11-01-5f6b2ab9fdb0"></a>
- **Radioimmunoassay of ganirelix in plasma or serum. · retained source version 1:2019-11-01:current:5f6b2ab9fdb0c3bab443257e5a2024daff3017747e478a5f826ec484b4b50b33** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8354719/) (`pubmed-observation-pmid-8354719-2019-11-01-5f6b2ab9fdb0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Radioimmunoassay of ganirelix in plasma or serum." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/ganirelix.json#pubmed-pmid-8354719-ganirelix-v1 SHA-256: f6e7573353139c56349a4379cec7b338e56597b9e2dba9ac07e2e064f41227a8.

